Treace Medical Concepts, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparison is with the three months ended March 31, 2023. Treace develops and sells surgical systems and related products for bunion and midfoot deformities, including its Lapiplasty system.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $51.1 million | $42.2 million; up 21.1% |
| Gross profit and margin | $41.0 million; 80.2% | $34.2 million; 80.9% |
| Operating expenses | $59.9 million | $47.9 million; up 25.1% |
| Operating loss | $19.0 million | $13.8 million |
| Net loss and diluted loss per share | $18.7 million; $0.30 | $13.5 million; $0.23 |
| Cash used in operating activities | $7.2 million | $17.3 million |
| Cash and cash equivalents | $9.3 million at March 31, 2024 | $13.0 million at December 31, 2023 |
| Short-term marketable securities | $100.7 million at March 31, 2024 | $110.2 million at December 31, 2023 |
| Debt principal outstanding | $54.0 million | $50.0 million term loan plus $4.0 million revolving balance |
Revenue growth reflected higher procedure-kit volume from an expanded surgeon customer base and increased adoption of newer technologies and complementary products. Gross margin slipped mainly due to product mix, partly offset by lower royalty rates. Sales and marketing, research and development, and general and administrative expenses all increased. Cash from operations improved year over year, with working-capital movements—including higher accounts payable and collections of receivables—contributing to the result. The company reported $3.9 million of property and equipment purchases, including reusable surgical instruments.
At March 31, current assets were $187.4 million and current liabilities were $47.0 million. The company said available cash, marketable securities, debt availability, and expected revenue should fund operations for at least 12 months from issuance of the financial statements. It also cautioned that assumptions may change and additional financing may be needed.
Outlook, commentary, and notable risks
- No specific revenue or earnings guidance was provided. Management expects revenue to increase in absolute dollars, but says it expects to continue operating at a loss in the near term and anticipates further investment and increases in sales and marketing, R&D, and general and administrative costs.
- Management cited increased competition, including minimally invasive osteotomy offerings and new Lapidus products, as potentially pressuring growth and market share. It also identified inflation, interest rates, supply-chain challenges, and economic conditions that may affect costs and demand for elective procedures.
- The business is seasonal: historically, the fourth quarter accounts for approximately 30%–40% of annual revenue, while the first and third quarters tend to be seasonally weaker.
- A customer filed for bankruptcy in May 2024. The March 31 accounts receivable balance included $2.0 million due from that customer before allowance; Treace is assessing collectability and the customer relationship.
- RPM-3D acquisition milestone terms were amended. Potential payments were reduced from a maximum of $10.0 million to $8.1 million, conditional on completion of a transition-services milestone; scheduled payments are $6.0 million in July 2024 and $2.1 million in January 2025 if the condition is met. The company expects to pay the $3.5 million technological-advancements milestone, subject to the stated conditions.
- Debt bears capped rates of 9% on the term loan and 7% on the revolving facility and is secured by substantially all company assets, including intellectual property. The company was not subject to the minimum-revenue covenant at quarter end. It reported no material legal proceedings and no material changes to previously disclosed risk factors.
- Management concluded disclosure controls were effective as of quarter end; it reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether revenue growth and surgeon adoption continue amid increased competition, and how product mix affects gross margin.
- Whether the $2.0 million bankruptcy-related receivable is collected and whether the customer relationship continues.
- Cash and marketable-securities use, operating cash flow, and the assumptions behind management’s at-least-12-month liquidity assessment.
- Whether RPM-3D milestone conditions are achieved and the timing and amount of any resulting payments.
- Debt availability and covenant requirements, alongside the company’s continued operating losses and planned expense growth.